# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $36 price...
-Ritedose is the development partner and manufacturer of Ohtuvayre (ensifentrine)*, the first inhaled product with a novel mech...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $36 price...
GSK's Phase 3 MATINEE trial of Nucala in COPD met the primary endpoint, reducing exacerbations significantly over 104 weeks.
Verona Pharma (NASDAQ:VRNA) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.38)...